Literature DB >> 2821876

Physiological effects of 4-aminopyridine on demyelinated mammalian motor and sensory fibers.

C M Bowe1, J D Kocsis, E F Targ, S G Waxman.   

Abstract

The selective response of demyelinated sensory fibers to 4-aminopyridine (4-AP) has been proposed as a mechanism underlying the reported paresthesias that complicate the use of this potassium-channel blocking agent in clinical trials for the treatment of multiple sclerosis and neuromuscular disorders. To identify differences in the electrophysiological response of specific fiber types to the application of 4-AP, rat ventral and dorsal spinal roots, demyelinated by intrathecal injections of lysophosphatidylcholine, were examined in vitro before and during potassium-channel blockade. The compound action potentials of demyelinated ventral roots showed a prominent postspike negativity associated with a broadening of single action potentials following application of 4-AP. Under similar conditions, whole root responses of demyelinated dorsal root axons also developed a late negativity, but individual fibers were observed to fire repetitively in response to a single stimulus. The data support the hypothesis that the prominent sensory dysfunctions reported in clinical trials of 4-AP are due to the selective response characteristics of sensory fibers.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2821876     DOI: 10.1002/ana.410220212

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  12 in total

1.  Cooperativity between remote sites of ectopic spiking allows afterdischarge to be initiated and maintained at different locations.

Authors:  Jay S Coggan; Terrence J Sejnowski; Steven A Prescott
Journal:  J Comput Neurosci       Date:  2015-05-01       Impact factor: 1.621

Review 2.  Peripheral nerve injury and myelination: Potential therapeutic strategies.

Authors:  Max Modrak; M A Hassan Talukder; Khatuna Gurgenashvili; Mark Noble; John C Elfar
Journal:  J Neurosci Res       Date:  2019-10-13       Impact factor: 4.164

3.  Diffusion tensor imaging detected optic nerve injury correlates with decreased compound action potentials after murine retinal ischemia.

Authors:  Qing Wang; Roman Vlkolinsky; Mingqiang Xie; Andre Obenaus; Sheng-Kwei Song
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-17       Impact factor: 4.799

4.  Potassium channel blockade differentially affects the relative refractory period of frog afferent terminals and axons.

Authors:  N C Tkacs; R D Wurster
Journal:  Cell Mol Neurobiol       Date:  1990-09       Impact factor: 5.046

5.  Morphologically identified cutaneous afferent DRG neurons express three different potassium currents in varying proportions.

Authors:  B Everill; M A Rizzo; J D Kocsis
Journal:  J Neurophysiol       Date:  1998-04       Impact factor: 2.714

Review 6.  The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease.

Authors:  K J Smith; W I McDonald
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

Review 7.  4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review.

Authors:  Henrik Boye Jensen; Mads Ravnborg; Ulrik Dalgas; Egon Stenager
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

8.  The effects of anticonvulsants on 4-aminopyridine-induced bursting: in vitro studies on rat peripheral nerve and dorsal roots.

Authors:  G Lees
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

9.  Fibroblast growth factor homologous factor 2B: association with Nav1.6 and selective colocalization at nodes of Ranvier of dorsal root axons.

Authors:  Ellen K Wittmack; Anthony M Rush; Matthew J Craner; Mitchell Goldfarb; Stephen G Waxman; Sulayman D Dib-Hajj
Journal:  J Neurosci       Date:  2004-07-28       Impact factor: 6.167

Review 10.  Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy).

Authors:  Andrew D Goodman; Robert Thompson Stone
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.